Scarica l'app Stockscreener
346.36
3.87%
12.89
Dopo l'orario di chiusura:
348.90
2.54
+0.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$333.47
Aprire:
$340.24
Volume 24 ore:
977.83K
Relative Volume:
1.67
Capitalizzazione di mercato:
$24.38B
Reddito:
$2.36B
Utile/perdita netta:
$236.10M
Rapporto P/E:
105.40
EPS:
3.286
Flusso di cassa netto:
$382.50M
1 W Prestazione:
+2.83%
1M Prestazione:
+8.72%
6M Prestazione:
+6.30%
1 anno Prestazione:
+32.20%
Intervallo 1D:
$336.82
$348.23
Intervallo di 1 settimana:
$324.97
$348.23
Portata 52W:
$230.05
$353.50
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Confronta PODD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
346.36 | 23.46B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
126.15 | 226.05B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.01 | 147.09B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.23 | 137.49B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.34 | 129.29B | 34.76B | 4.79B | 5.30B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
86.02 | 48.77B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
Will Insulet Corporation (GOV) stock benefit from Fed rate cutsFed Meeting & Capital Protection Trading Alerts - newser.com
Is Insulet Corporation (GOV) stock at risk of policy regulationEarnings Overview Summary & Advanced Technical Signal Analysis - newser.com
Will Insulet Corporation (GOV) stock deliver compounding returnsEarnings Performance Report & Risk Managed Investment Entry Signals - newser.com
Insulet stock rating upgraded to Buy by UBS on Type 2 diabetes opportunity - Investing.com South Africa
How analysts revise price targets for Insulet Corporation (GOV) stockJuly 2025 Pullbacks & High Yield Stock Recommendations - newser.com
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Shares Rise After UBS Upgrade - MarketScreener
Insulet upgraded at UBS ahead of analyst day on growth prospects - MSN
Insulet (PODD) Upgraded by UBS with a New Price Target of $400 | - GuruFocus
Why retail investors pile into Insulet Corporation stockRecession Risk & Safe Entry Trade Signal Reports - newser.com
UBS Upgrades Insulet to Buy From Neutral - MarketScreener
How to monitor Insulet Corporation with trend dashboardsJuly 2025 Update & Free Long-Term Investment Growth Plans - newser.com
UBS Upgrades Insulet Corporation (PODD) to Buy - StreetInsider
What machine learning models say about Insulet CorporationWeekly Stock Report & Low Risk High Win Rate Stock Picks - newser.com
Why (PODD) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Insulet stock rating upgraded by UBS on Type 2 diabetes growth potential - Investing.com
Chart based exit strategy for Insulet CorporationStop Loss & Safe Entry Momentum Tips - newser.com
Will Insulet Corporation stock recover after recent dropForecast Cut & Smart Money Movement Alerts - newser.com
Sector ETF performance correlation with Insulet CorporationBreakout Watch & High Yield Stock Recommendations - newser.com
Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion - Yahoo Finance
Multi asset correlation models including Insulet CorporationQuarterly Earnings Summary & Weekly Sector Rotation Insights - newser.com
3 Reasons We Love Insulet (PODD) - Finviz
Do Options Traders Know Something About Insulet Stock We Don't? - sharewise.com
Will Insulet Corporation rebound enough to break evenPortfolio Value Report & Long Hold Capital Preservation Tips - newser.com
What technical signals suggest for Insulet Corporation stock2025 Volatility Report & Precise Swing Trade Entry Alerts - newser.com
Why Insulet Corporation (GOV) stock stays resilientJuly 2025 Opening Moves & Weekly Momentum Stock Picks - newser.com
Best data tools to analyze Insulet Corporation stockJuly 2025 Review & Safe Capital Investment Plans - newser.com
Why Insulet Corporation (GOV) stock could outperform next year2025 Volatility Report & Consistent Growth Stock Picks - newser.com
Why Insulet Corporation stock appeals to dividend seekers2025 Top Decliners & AI Driven Price Predictions - newser.com
Can Insulet Corporation stock sustain revenue growthEarnings Recap Summary & Reliable Entry Point Trade Alerts - newser.com
Will Insulet Corporation outperform the marketMarket Trend Review & Safe Swing Trade Setup Alerts - newser.com
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.89%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):